Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

patent

The articles shown below are all about the patent, through these related articles, you can get relevant information, notes in use, or latest trends about the patent. We hope these news will give you the help you need. And if these patent articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of July 07 2025

    2025-07-07

    This week, there are 13 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's BIKTARVY, containing active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's VEMLIDY, containing active ingredient TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's GENVOYA, containing active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's DESCOVY, containing active ingredient EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - ANI PHARMACEUTICALS INC's VEREGEN, containing active ingredient SINECATECHINS - NOVARTIS PHARMACEUTICALS CORP's PROMACTA KIT, containing active ingredient ELTROMBOPAG OLAMINE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 30 2025

    2025-06-30

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - EAGLE PHARMACEUTICALS INC's RYANODEX, containing active ingredient DANTROLENE SODIUM - ULTRAGENYX PHARMACEUTICAL INC's DOJOLVI, containing active ingredient TRIHEPTANOIN - VIIV HEALTHCARE CO's RUKOBIA, containing active ingredient FOSTEMSAVIR TROMETHAMINE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 23 2025

    2025-06-23

    This week, there are 18 drugs in the patent and exclusivity list. They are: - SUNOVION PHARMACEUTICALS INC's LATUDA, containing active ingredient LURASIDONE HYDROCHLORIDE - VERTEX PHARMACEUTICALS INC's TRIKAFTA (COPACKAGED), containing active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - VERTEX PHARMACEUTICALS INC's KALYDECO, containing active ingredient IVACAFTOR - VERTEX PHARMACEUTICALS INC's SYMDEKO (COPACKAGED), containing active ingredient IVACAFTOR; IVACAFTOR, TEZACAFTOR - TAKEDA PHARMACEUTICALS USA INC's KAZANO, containing active ingredient ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - VERTEX PHARMACEUTICALS INC's ALYFTREK, containing active ingredient DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 16 2025

    2025-06-16

    This week, there are 9 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's POMALYST, containing active ingredient POMALIDOMIDE - VIATRIS SPECIALTY LLC's TOBI PODHALER, containing active ingredient TOBRAMYCIN - RHYTHM PHARMACEUTICALS INC's IMCIVREE, containing active ingredient SETMELANOTIDE ACETATE - PF PRISM CV's BOSULIF, containing active ingredient BOSUTINIB MONOHYDRATE - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - BPI LABS LLC's ABLYSINOL, containing active ingredient ALCOHOL - HORIZON THERAPEUTICS USA INC's PROCYSBI, containing active ingredient CYSTEAMINE BITARTRATE - NOVARTIS PHARMACEUTICALS CORP's TAFINLAR, containing active ingredient DABRAFENIB MESYLATE - NOVARTIS PHARMACEUTICALS CORP's MEKINIST, containing active ingredient TRAMETINIB DIMETHYL SULFOXIDE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 09 2025

    2025-06-09

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's TAFINLAR, containing active ingredient DABRAFENIB MESYLATE - NOVARTIS PHARMACEUTICALS CORP's MEKINIST, containing active ingredient TRAMETINIB DIMETHYL SULFOXIDE - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - ELI LILLY AND CO's OLUMIANT, containing active ingredient BARICITINIB - MEDICINES DEVELOPMENT FOR GLOBAL HEALTH's MOXIDECTIN, containing active ingredient MOXIDECTIN - JAZZ PHARMACEUTICALS IRELAND LTD's ZEPZELCA, containing active ingredient LURBINECTEDIN Read More
  • Drug Patent & Exclusivity Expiration Report - Week of June 02 2025

    2025-06-02

    This week, there are 5 drugs in the patent and exclusivity list. They are: - PARATEK PHARMACEUTICALS INC's NUZYRA, containing active ingredient OMADACYCLINE TOSYLATE - SANDOZ INC's CIPRODEX, containing active ingredient CIPROFLOXACIN; DEXAMETHASONE - BRAEBURN INC's BRIXADI, containing active ingredient BUPRENORPHINE - INSMED INC's ARIKAYCE KIT, containing active ingredient AMIKACIN SULFATE - ABBVIE INC's VENCLEXTA, containing active ingredient VENETOCLAX Read More
  • Drug Briefing: Tirzepatide

    2025-05-29

    Query Drug:TirzepatideQuery Time:2025-05-29 16:35:52*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of May 26 2025

    2025-05-26

    This week, there are 11 drugs in the patent and exclusivity list. They are: - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's SPIRIVA RESPIMAT, containing active ingredient TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's COMBIVENT RESPIMAT, containing active ingredient ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STIOLTO RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - BOEHRINGER INGELHEIM PHARMACEUTICALS INC's STRIVERDI RESPIMAT, containing active ingredient OLODATEROL HYDROCHLORIDE - ALNYLAM PHARMACEUTICALS INC's ONPATTRO, containing active ingredient PATISIRAN SODIUM - ACROTECH BIOPHARMA INC's FOLOTYN, containing active ingredient PRALATREXATE - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE - SALIX PHARMACEUTICALS INC's XIFAXAN, containing active ingredient RIFAXIMIN - FRESENIUS KABI USA LLC's DIPRIVAN, containing active ingredient PROPOFOL Read More
  • Drug Patent & Exclusivity Expiration Report - Week of May 19 2025

    2025-05-19

    This week, there are 15 drugs in the patent and exclusivity list. They are: - TEVA PHARMACEUTICAL INDUSTRIES LTD's AIRDUO RESPICLICK, containing active ingredient FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC's PROAIR RESPICLICK, containing active ingredient ALBUTEROL SULFATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's TRELEGY ELLIPTA, containing active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE's BREO ELLIPTA, containing active ingredient FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - AZURITY PHARMACEUTICALS INC's EDARBYCLOR, containing active ingredient AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE Read More
  • Total 5 pages  Go to Page
  • Go